Anika projects 2026 adjusted EBITDA margin of 13% to 17% as it raises revenue growth outlook to 5% to 10% (NASDAQ:ANIK)
· seekingalpha.com
Anika Therapeutics (ANIK) Q2 2026 earnings call recap: record commercial growth, 65% gross margin, higher 2026 guidance, Hyalofast risks—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...